A fixed-dose combination of two natural glycosaminoglycans used as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). Glucosamine is an amino sugar and a precursor for glycosaminoglycans, a major component of joint cartilage. Chondroitin sulfate is a sulfated glycosaminoglycan that provides cartilage with its compressive resistance. In the Indian context, this combination is widely used as a prescription and over-the-counter nutraceutical for the management of mild to moderate osteoarthritis, particularly of the knee. It is considered a disease-modifying agent with potential to slow radiographic progression, though evidence is debated.
Adult: One tablet/capsule of Glucosamine 500mg + Chondroitin 400mg, taken orally two to three times daily, or as a single daily dose of 1500mg Glucosamine + 1200mg Chondroitin. Commonly prescribed as one tablet thrice daily.
Note: Take with or after meals to improve gastrointestinal tolerance. Swallow whole with a full glass of water. Consistent daily intake is crucial for therapeutic effect. Therapy should be continued for a minimum of 3-6 months to assess efficacy.
The combination exerts a multi-modal chondroprotective and anti-inflammatory effect. Glucosamine provides the fundamental substrate for the biosynthesis of glycosaminoglycans (GAGs) and hyaluronic acid, stimulating proteoglycan production in chondrocytes. Chondroitin sulfate attracts water into the cartilage matrix, providing compressive resilience, and inhibits degradative enzymes like matrix metalloproteinases (MMPs), hyaluronidase, and elastase. Together, they may downregulate pro-inflammatory cytokines (IL-1β, TNF-α, COX-2, PGE2) and NF-κB pathway activity, reducing cartilage catabolism.
Pregnancy: Category C (US FDA). Animal reproduction studies have not been conducted. Not recommended during pregnancy due to lack of safety data. Use only if potential benefit justifies potential risk.
Driving: Drowsiness has been reported rarely. Patients should exercise caution until they know how the medication affects them.
| Warfarin and other Coumarin Anticoagulants | Chondroitin may have mild anticoagulant properties. Potential for increased INR and bleeding risk. Monitor INR closely. | Major |
| Acetaminophen (Paracetamol) | Theoretical competition for sulfation pathways. Clinical significance is unclear. | Moderate |
| Chemotherapy agents (e.g., Doxorubicin, Etoposide) | Glucosamine may interfere with the action of some chemotherapeutic drugs by affecting hexosamine pathway. Avoid concurrent use. | Major |
| Antidiabetic Drugs (Insulin, Metformin, Sulfonylureas) | Conflicting data on glucosamine affecting insulin resistance or glucose metabolism. Monitor blood glucose levels in diabetics. | Moderate |
| Tetracycline antibiotics | Possible reduced absorption of tetracycline. Separate administration by 2-3 hours. | Moderate |
Same composition (Glucosamine (500mg) + Chondroitin (400mg)), different brands: